Linda Coley Sewell Distinguished Professor of Medicine
University of North Carolina at Chapel Hill
Chapel Hill, NC, United States
Dr. Saira Sheikh is the Linda Coley Sewell Distinguished Professor of Medicine at the University of North Carolina at Chapel Hill. She is trained and board certified in Internal Medicine, Allergy/Immunology and Rheumatology. She is the Director of the Clinical Trials Program at the University of North Carolina's (UNC) Thurston Arthritis Research Center (TARC), as well as the UNC Rheumatology Lupus Clinic. Her work focuses on answering scientific questions that directly impact the care of patients with complex immunologic diseases. She is also leading national initiatives to develop real-world, practical models to promote inclusion of minority patients in lupus clinical trials, particularly using technology-based applications. She is Vice-Chair of the Lupus Clinical Investigators Network (LuCIN). She currently serves on the Medical-Scientific Advisory Council for the Lupus Foundation of America.
Practical Programs to Engage Diverse Participants in Lupus Clinical Trials
Sunday, November 12, 2023
12:00 PM – 12:20 PM PT
Disclosure(s): AstraZeneca: Consultant (Terminated, October 7, 2022); Aurinia Pharmaceuticals Inc.: Consultant (Terminated, September 18, 2021); Biogen: Consultant (Terminated, August 24, 2022); GSK: Advisor or Review Panel Member (Ongoing); Lilly USA: Consultant (Terminated, November 19, 2021); Pfizer: Grant/Research Support (Terminated, January 1, 2022)
Monday, November 13, 2023
9:00 AM – 11:00 AM PT
Disclosure(s): AstraZeneca: Consultant (Terminated, October 7, 2022); Aurinia Pharmaceuticals Inc.: Consultant (Terminated, September 18, 2021); Biogen: Consultant (Terminated, August 24, 2022); GSK: Advisor or Review Panel Member (Ongoing); Lilly USA: Consultant (Terminated, November 19, 2021); Pfizer: Grant/Research Support (Terminated, January 1, 2022)
Monday, November 13, 2023
9:00 AM – 11:00 AM PT
Disclosure(s): AstraZeneca: Consultant (Terminated, October 7, 2022); Aurinia Pharmaceuticals Inc.: Consultant (Terminated, September 18, 2021); Biogen: Consultant (Terminated, August 24, 2022); GSK: Advisor or Review Panel Member (Ongoing); Lilly USA: Consultant (Terminated, November 19, 2021); Pfizer: Grant/Research Support (Terminated, January 1, 2022)
Practical Models to Enhance/Promote Racial and Ethnic Inclusion in Lupus Clinical Trials
Tuesday, November 14, 2023
8:00 AM – 8:15 AM PT
Disclosure(s): AstraZeneca: Consultant (Terminated, October 7, 2022); Aurinia Pharmaceuticals Inc.: Consultant (Terminated, September 18, 2021); Biogen: Consultant (Terminated, August 24, 2022); GSK: Advisor or Review Panel Member (Ongoing); Lilly USA: Consultant (Terminated, November 19, 2021); Pfizer: Grant/Research Support (Terminated, January 1, 2022)
Tuesday, November 14, 2023
9:00 AM – 11:00 AM PT
Disclosure(s): AstraZeneca: Consultant (Terminated, October 7, 2022); Aurinia Pharmaceuticals Inc.: Consultant (Terminated, September 18, 2021); Biogen: Consultant (Terminated, August 24, 2022); GSK: Advisor or Review Panel Member (Ongoing); Lilly USA: Consultant (Terminated, November 19, 2021); Pfizer: Grant/Research Support (Terminated, January 1, 2022)
Tuesday, November 14, 2023
9:00 AM – 11:00 AM PT
Disclosure(s): AstraZeneca: Consultant (Terminated, October 7, 2022); Aurinia Pharmaceuticals Inc.: Consultant (Terminated, September 18, 2021); Biogen: Consultant (Terminated, August 24, 2022); GSK: Advisor or Review Panel Member (Ongoing); Lilly USA: Consultant (Terminated, November 19, 2021); Pfizer: Grant/Research Support (Terminated, January 1, 2022)